Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Palau Science & Technology Journal.
Press releases published on August 29, 2025
AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service
GlobeNewswire
·
August 29, 2025
Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA). AMALFI tested whether home-based, self-applied use of iRhythm’s …
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
GlobeNewswire
·
August 29, 2025
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in …
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 29, 2025
NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats …
Alumis to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
August 29, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will …
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
GlobeNewswire
·
August 29, 2025
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global …
Aduro Clean Technologies Initiates Marketing Campaign
GlobeNewswire
·
August 29, 2025
LONDON, Ontario, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste …
BullZilla Presale Launches on Aug 29 with Mutation Mechanism and Staking Rewards
GlobeNewswire
·
August 29, 2025
LONDON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The meme coin battlefield is about to awaken as BullZilla ($BZIL), an Ethereum-powered ERC-20 token, announces the launch of its highly anticipated presale. The event starts on August 29, 2025, at 6:00 p.m. GMT, …
Pandag Tech's G1 Robotic Mower Draws Strong Interest at Major Australian Agricultural Events
GlobeNewswire
·
August 29, 2025
GUNNEDAH, Australia, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pandag Tech marked a successful Australian market debut at AgQuip and Dowerin Field Day this month, with its flagship Pandag G1 robotic mower drawing lots of professional visitors and generating …
Panasonic TOUGBOOK Showcases Mission-Ready Defence Solutions at DSEI 2025
GlobeNewswire
·
August 29, 2025
Panasonic TOUGHBOOK to deliver immersive demonstrations of rugged, mission-ready technology aligned with the UK’s Strategic Defence Review (SDR) 2025, supporting national security and NATO interoperability at DSEI London. Bracknell, UK. 29th August 2025 – …
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms …
RNA Polymerase I POL 1 Clinical Trials Companies FDA Approval Development Trends Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global RNA Polymerase I Clinical Trials, Development Trends By Indications, Target Approaches …
Tetraspecific Antibodies Clinical Trials FDA Approval Development Technologies Platforms Market Opportunity Companies Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Therapeutic Approaches …
Bispecific Antibody Drug Conjugates ADC Clinical Trials FDA Approval Companies Commercial Launch Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape and Market Opportunity Insight 2025 Report Findings and Highlights: First Bispecific Antibody Drug Conjugate …
Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Research Methodology Followed Global and Regional Market Overview Global …
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
GlobeNewswire
·
August 29, 2025
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive …
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale
GlobeNewswire
·
August 29, 2025
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale NANTES, France - 29 août 2025, 8h00 CET – OSE Immunotherapeutics SA (ISIN: …
Santhera schliesst Vereinbarung mit Ikris Pharma Network über den Vertrieb von AGAMREE® (Vamorolon) in Indien
GlobeNewswire
·
August 29, 2025
Pratteln, Schweiz, 29. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Ikris Pharma Network (Ikris) über den Vertrieb von AGAMREE® (Vamorolon) in Indien zur Behandlung von Duchenne- …
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
GlobeNewswire
·
August 29, 2025
Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne …
American Rebel Holdings Clarifies: No Amended S-1 Filed on August 28; Webull/Benzinga Posts Mischaracterized Prior June 3 Filing
GlobeNewswire
·
August 29, 2025
After fielding multiple investor calls prompted by misleading August 28 Benzinga posts, the Company confirms no new S-1/A was filed; the referenced amendment was filed June 3, 2025, and the referenced registration was declared effective June 27, 2025. …
Snail Games 凭借新里程碑、行业活动及即将发布的作品推进多品牌发行战略
GlobeNewswire
·
August 29, 2025
卡尔弗城，加利福尼亚州, Aug. 29, 2025 (GLOBE NEWSWIRE) -- 作为全球领先的互动数字娱乐独立开发商和发行商，Snail, Inc.（Nasdaq：SNAL，以下称为“Snail Games”或“公司”）今日重点展示了其旗下各发行品牌所取得的一系列里程碑成果。 这些进展凸显了公司在多平台、多类型游戏及各类行业活动中灵活运作的能力，进一步彰显了 Snail 持续推进的广泛市场参与和增长战略。 Snail Games 与 Studio Sirens 联手在 Epic …